ADMA vs GRFS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GRFS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADMA and GRFS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADMA and GRFS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

ADMA Biologics is an end-to-end biopharmaceutical company focused on plasma-derived therapies. It develops, manufactures, and markets immunoglobulin (IG) products and operates its own plasma-collection centers, giving it control over part of the supply chain that feeds its manufacturing. Its FDA-approved products include Asceniv, an intravenous immune globulin used to treat primary immunodeficiency, Bivigam, a standard intravenous immune globulin, and Nabi-HB for hepatitis B exposure. Asceniv is the company's differentiated, higher-value product and has been the main growth driver, while Bivigam competes in the more crowded standard-IG market.

Full ADMA guide

Grifols, S.A. is a Spanish healthcare company founded in Barcelona in 1909 and one of the three dominant players in the global blood-plasma industry, alongside CSL and Takeda. It collects human plasma through a large network of donation centers (heavily concentrated in the United States) and fractionates it into therapies, most importantly immunoglobulins (IVIG and subcutaneous Ig) used for immune deficiencies and neurological conditions, plus albumin, alpha-1 antitrypsin, and clotting factors. The business also includes a diagnostics division (blood typing, transfusion screening) and a bio-supplies arm. Revenue comes from selling these plasma-derived medicines to hospitals, specialty pharmacies, and health systems worldwide, with the immunoglobulin franchise the single largest and fastest-growing driver. Grifols trades on the Spanish exchanges under Class A (GRF) and non-voting Class B (GRF.P) shares, and in the US as ADRs under the ticker GRFS.

Full GRFS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ADMA drivers: Asceniv, the specialty growth driver; Integrated plasma-collection model.
• GRFS drivers: Immunoglobulin demand and volume growth; Margin recovery from lower cost-per-liter.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue and led ADMA in 2026 to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics. For GRFS, grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADMA if you believe its drivers more; GRFS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADMA and GRFS guides.

ADMA. Figures are approximate and tied to the asOf date; verify live numbers before acting. ADMA is profitable, so an earnings multiple is meaningful, but the 2026 guidance cut and withdrawn long-term targets make forward estimates less certain than before, so investors should weigh the durability of Asceniv growth against standard-IG competition rather than rely on a single multiple. The mix shift toward specialty product matters more here than headline revenue, which stayed flat.

GRFS. As of July 2026 Grifols trades at a discount to plasma peers like CSL, reflecting its higher leverage and the residual governance overhang rather than weak operations. On enterprise-value terms the shares look inexpensive against roughly EUR 1.8 billion of adjusted EBITDA, but the large net-debt position means most of that enterprise value still sits with lenders, which is exactly why deleveraging is the key equity lever. Analysts generally rate the ADR in the Hold-to-Moderate-Buy range with price targets clustered around $10 to $12.50.

Headline figures (approximate, Jul 2026): ADMA shows revenue (q1 2026) ~$114.5 million, roughly flat year over year, eps (q1 2026) ~$0.19, up about 73% year over year, product mix trend Asceniv revenue up ~28%; Bivigam down ~54%, 2026 revenue guidance cut to ~$530 to $560 million (from a prior view above $635 million); GRFS shows revenue (fy 2025) ~EUR 7.5 billion (~$8.2 billion), adjusted ebitda (fy 2025) ~EUR 1.8 billion (~24% margin), net profit (fy 2025) ~EUR 402 million (more than doubled YoY), q1 2026 revenue ~EUR 1.7 billion (+3.3% cc).

ADMA and GRFS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADMA and GRFS exposure against your real portfolio. It is not an investment adviser.